VEGF C Rat
Greater than 90.0% as determined by SDS-PAGE.
Description
Vascular Endothelial Growth Factor C Rat Recombinant contains 127 amino acids residues and was fused to a His- tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 15-20 kDa protein in SDS-PAGE under reducing conditions.
Product Specs
Product Science Overview
Vascular Endothelial Growth Factor (VEGF) is a signal protein that stimulates the formation of blood vessels. It plays a crucial role in both physiological and pathological angiogenesis. VEGF is particularly significant in the context of cardiovascular diseases, cancer, and various other conditions where blood vessel formation is a key factor .
VEGF is an endothelial cell-specific mitogen that promotes the proliferation and migration of endothelial cells. It is also known to increase vascular permeability, which is why it was initially referred to as Vascular Permeability Factor (VPF) . VEGF operates through binding to its receptors, primarily VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), which are tyrosine kinase receptors .
Recombinant VEGF proteins, such as those derived from rats, are widely used in research to study their effects on angiogenesis and related processes. These recombinant proteins are produced using genetic engineering techniques, where the VEGF gene is inserted into a host organism, often bacteria or yeast, to produce the protein in large quantities .
Recombinant VEGF proteins are used in various disease models to understand their role in conditions like ischemic heart disease, cancer, and diabetic retinopathy. For instance, VEGF-based therapies have shown promise in preclinical studies for promoting angiogenesis in ischemic tissues . Additionally, anti-VEGF therapies are being explored for their potential to inhibit tumor growth by preventing the formation of new blood vessels that supply the tumor .
